Galectin Therapeutics Inc. (GALT)

[thefamilyman]

My fear is that they have underestimated the dosage necessary to achieve the spectacular results experienced in the animal model. That would be a shame since the drug is apparently very safe and they could have easily included a Cohort 4 at a higher dose in the Phase 1 trial. Now all we can do is wait and see...

"At least they are beginning to admit that the entire future of the company is solely dependent on the outcome of the CX trial, something they say was designed to have an 80% chance of success. Of course that doesn't mean it actually has an 80% chance of success, it just means that if the drug essentially works there is an 80% chance that the trial design will identify the success." - biotech2010